Sign In
Buy ZLDPF
$49.02
+0 (+0%)
At Close: Jun 03, 2026
Roche to develop, commercialize obesity drug with Zealand Pharma
02:17am, Wednesday, 12'th Mar 2025
Roche has entered an exclusive collaboration and licensing agreement with Danish obesity drug maker Zealand Pharma to co-develop petrelintide as an obesity therapy drug, the Swiss company said on Wedn
Zealand Pharma A/S (ZLDPF) Q4 2024 Earnings Call Transcript
03:25pm, Thursday, 20'th Feb 2025
Zealand Pharma A/S (OTCPK:ZLDPF) Q4 2024 Earnings Conference Call February 20, 2025 8:00 AM ET Company Participants Anna Krassowska - VP, IR Adam Steensberg - President and Chief Executive Officer Dav
Zealand Pharma conference call on February 20 at 2pm CET (8am ET) to present full year 2024 financial results
11:00am, Thursday, 13'th Feb 2025
Press Release – No. 3 / 2025 Zealand Pharma conference call on February 20 at 2pm CET (8am ET) to present full year 2024 financial results Copenhagen, Denmark, February 13, 2025 – Zealand Pharm
Zealand Pharma CEO says Novo's CagriSema data supports monotherapy approach to cagrilintide
08:55am, Friday, 20'th Dec 2024
The CEO of Danish drugmaker Zealand Pharma said on Friday that data posted by Novo Nordisk's late-stage study of its next-generation obesity drug CagriSema supported Zealand's own monotherapy approach
US FDA declines to approve Zealand Pharma's bowel disease drug
03:08pm, Thursday, 19'th Dec 2024
The U.S. Food and Drug Administration declined to approve Zealand Pharma's bowel disease drug, the company said on Thursday.
Zealand Pharma And Eli Lilly: Strategic Focus On Weight Management And Future Outlook
07:00am, Thursday, 19'th Dec 2024
Eli Lilly's diverse product portfolio and promising pipeline, including Tirzepatide, Orforglipron, and Retatrutide, support a "buy" rating for long-term investors despite current valuation metrics. Ze
Zealand Pharma starts Phase 2b trial for obesity drug candidate petrelintide
09:12am, Tuesday, 10'th Dec 2024
Danish biotechnology company Zealand Pharma said on Tuesday it had enrolled the first patient in its so-called Phase 2b ZUPREME-1 trial with its obesity treatment candidate petrelintide.
Zealand Pharma A/S (ZLDPF) Reports Q3 Loss, Lags Revenue Estimates
08:06am, Thursday, 07'th Nov 2024
Zealand Pharma A/S (ZLDPF) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.62. This compares to earnings of $0.18 per share a year ago.
Zealand Pharma to start phase 2b trial for obesity drug candidate in Q4
01:20am, Thursday, 07'th Nov 2024
Danish biotechnology company Zealand Pharma said on Thursday it expected to initiate a phase 2b trial with its obesity treatment candidate petrelintide in the fourth quarter of 2024.
Zealand Pharma conference call on November 7 at 2pm CET (8am ET) to present third quarter 2024 financial results
12:30pm, Friday, 01'st Nov 2024
Press Release – No. 10 / 2024 Zealand Pharma conference call on November 7 at 2pm CET (8am ET) to present third quarter 2024 financial results Copenhagen, Denmark, November 1, 2024 – Zealand Ph
Zealand Pharma seeks partner for its 'next generation' weight loss drug
09:34pm, Sunday, 13'th Oct 2024
CNBC's Karen Gilchrist weighs in on Zealand Pharma's "next generation" obesity drug candidate and its search for a global partner.
Zealand Pharma targeting 'next generation' of obesity drugs, CEO says
09:27pm, Sunday, 13'th Oct 2024
Zealand Pharma's CEO Adam Steensberg weighs in on early-stage trials of its obesity drug contender and talks down takeover speculation.
Wegovy and Zepbound rival targeting 'next generation' of obesity drugs, Zealand Pharma CEO says
01:40am, Friday, 11'th Oct 2024
Danish biotech Zealand Pharma is targeting the "next generation" of weight loss drugs as competitors pile into a market dominated by heavyweights Novo Nordisk and Eli Lilly. CEO Adam Steensberg heral
Recent Price Trend in Zealand Pharma AS (ZLDPF) is Your Friend, Here's Why
09:50am, Thursday, 19'th Sep 2024
Zealand Pharma AS (ZLDPF) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Zealand Pharma AS (ZLDPF) Is a Great Choice for 'Trend' Investors, Here's Why
09:51am, Tuesday, 03'rd Sep 2024
Zealand Pharma AS (ZLDPF) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it t
